Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: Catfish who wrote (20217)	4/28/2004 10:04:56 AM
From: Catfish	Respond to of 120405

TBIO - 1.63/1.65 Stock has been in a down trend, but is trying to reverse with this PR out this AM: Transgenomic Inc. Continues to Provide Specialty Nucleic Acid Products to Geron Corporation Wednesday April 28, 6:02 am ET Ongoing Support for Manufacture of Geron's Novel Cancer Therapeutic OMAHA, Neb., April 28 /PRNewswire-FirstCall/ -- Transgenomic Inc. (Nasdaq: TBIO - News) announced today it has agreed to provide additional quantities of modified nucleic acid building block compounds to Geron Corporation (Nasdaq: GERN - News) under terms of multiple new addendums to an existing Master Supply Agreement between the two companies. The compounds will be used in the synthesis of Geron's anti-cancer drug GRN163L. GRN163L is a thio-phosphoramidate oligonucleotide, a new class of synthetic nucleic acid that has a number of potential advantages over earlier-generation synthetic nucleic acid chemistries, including enhanced sequence-specific DNA and RNA binding activity, high resistance to degradation, and improved uptake and biodistribution properties. Product shipments under the new addendums commenced in the first quarter of 2004 and are expected to extend into the third quarter. ADVERTISEMENT "We are pleased to have the opportunity to provide ongoing manufacturing support to Geron as they continue to develop their novel cancer therapeutics," said Collin D'Silva, Transgenomic's CEO. "We are well positioned to provide process development and manufacturing support for cutting-edge nucleic acid chemistries, such as the phosphoramidate-based chemistry upon which their lead molecules are based." D'Silva concluded, "We continue to sharpen our nucleic acid building block manufacturing operation's focus on supporting the manufacture of innovative, next-generation synthetic nucleic acids, a market segment in which we have a significant competitive edge." About Transgenomic Transgenomic provides versatile and innovative research tools and related consumable products to the life sciences industry for the synthesis, separation, analysis and purification of nucleic acids and a wide variety of nucleic acid-based specialty chemicals. Transgenomic's BioSystems segment offers its WAVE Systems® and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. These systems have broad applicability to genetic research and molecular diagnostics. To date there have been over one thousand systems installed in over 30 countries around the world. In addition, the BioSystems segment offers WAVE-based biomarker discovery and validation services in support of translational research, pre-clinical and clinical studies. Through its nucleic acids business segment, Transgenomic provides specialty chemicals, including advanced nucleic acid building blocks and associated reagents, used in applications such as genetic diagnostics and therapeutics, as well as a comprehensive menu of services, including nucleic acid chemistry R&D, process development, analytical methods development, cGMP oligonucleotide manufacturing, quality control and regulatory support. For more information about the innovative genomics research tools developed and marketed by Transgenomic, please visit the company's Web site at www.transgenomic.com.